CBL Antibody, HRP conjugated
CSB-PA004578LB01HU
ApplicationsELISA
Product group Antibodies
ReactivityHuman
TargetCBL
Overview
- SupplierCusabio
- Product NameCBL Antibody, HRP conjugated
- Delivery Days Customer20
- ApplicationsELISA
- CertificationResearch Use Only
- ClonalityPolyclonal
- ConjugateHRP
- Gene ID867
- Target nameCBL
- Target descriptionCbl proto-oncogene
- Target synonymsC-CBL, CBL2, FRA11B, NSLL, RNF55, E3 ubiquitin-protein ligase CBL, Cas-Br-M (murine) ecotropic retroviral transforming sequence, Cbl proto-oncogene, E3 ubiquitin protein ligase, RING finger protein 55, RING-type E3 ubiquitin transferase CBL, casitas B-lineage lymphoma proto-oncogene, fragile site, folic acid type, rare, fra(11)(q23.3), oncogene CBL2, proto-oncogene c-Cbl, signal transduction protein CBL
- HostRabbit
- IsotypeIgG
- Protein IDP22681
- Protein NameE3 ubiquitin-protein ligase CBL
- Scientific DescriptionAdapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The Tyr-731 phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3.
- ReactivityHuman
- Storage Instruction-20°C or -80°C
- UNSPSC41116161





